"The clap" redirects here. For other uses, see Clap.
Gonorrhea |
Classification and external resources |
During WWII, the US government used posters to warn servicemen about the dangers of gonorrhea and other sexually transmitted infections. |
ICD-10 |
A54 |
ICD-9 |
098 |
MedlinePlus |
007267 |
eMedicine |
article/782913 |
MeSH |
D006069 |
Gonorrhea (also colloquially known as the clap[1]) is a common human sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. The usual symptoms in men are burning with urination and penile discharge. Women, on the other hand, are asymptomatic half the time or have vaginal discharge and pelvic pain. In both men and women if gonorrhea is left untreated, it may spread locally causing epididymitis or pelvic inflammatory disease or throughout the body, affecting joints and heart valves.
Treatment is commonly with ceftriaxone as antibiotic resistance has developed to many previously used medications.
In 2011, there were reports of some strains of gonorrhea showing resistance to ceftriaxone.[2]
Contents
- 1 Signs and symptoms
- 2 Cause
- 3 Diagnosis
- 4 Screening
- 5 Prevention
- 6 Treatment
- 7 Complications
- 8 Epidemiology
- 9 History
- 10 References
- 11 External links
|
Signs and symptoms
Half of women with gonorrhea are asymptomatic while others have vaginal discharge, lower abdominal pain or pain with intercourse.[3] Most men who are infected have symptoms such as urethritis associated with burning with urination and discharge from the penis.[3] Either sex may also acquire gonorrhea of the throat from performing oral sex on an infected partner, usually a male partner. Such infection is asymptomatic in 90% of cases, and produces a sore throat in the remaining 10%.[4] The incubation period is 2 to 14 days with most of these symptoms occurring between 4–6 days after being infected.[5] Rarely, gonorrhea may cause skin lesions and joint infection (pain and swelling in the joints) after traveling through the blood stream (see below). Very rarely it may settle in the heart causing endocarditis or in the spinal column causing meningitis (both are more likely among individuals with suppressed immune systems, however).[4]
Cause
Gonorrhea is caused by the bacteria Neisseria gonorrhoeae.[3] The infection is transmitted from one person to another through vaginal, oral, or anal sex.[3] Men have a 20% risk of getting the infection from a single act of vaginal intercourse with an infected woman. The risk for men who have sex with men is higher.[6] Women have a 60–80% risk of getting the infection from a single act of vaginal intercourse with an infected man.[7] A mother may transmit gonorrhea to her newborn during childbirth; when affecting the infant's eyes, it is referred to as ophthalmia neonatorum.[3] It cannot be spread by toilets or bathrooms.[8]
Diagnosis
Traditionally, gonorrhea was diagnosed with gram stain and culture; however, newer polymerase chain reaction (PCR) based testing methods are becoming more common.[9] In those who fail initial treatment culture should be done to determine sensitivity to antibiotics.[10] All people who test positive for gonorrhea should be tested for other sexually transmitted diseases such as chlamydia, syphilis and human immunodeficiency virus.[10]
Screening
The United States Preventive Services Task Force recommends screening for gonorrhea in women at increased risk of infection which includes all sexually active women younger than 25 years. It is not recommended in males without symptoms or low risk women.[11]
Prevention
While the only sure way of preventing gonorrhea is abstaining from sexual intercourse, the risk of infection can be reduced significantly by using condoms correctly and by having a mutually monogamous relationship with an uninfected person.[12][13]
Treatment
Penicillin entered mass production in 1944 and revolutionized the treatment of several venereal diseases.
Gonorrhea if left untreated may last for weeks or months with higher risks of complications.[3] As of 2010 injectable ceftriaxone appears to be one of the few effective antibiotics.[10] Because of increasing rates of antibiotic resistance local susceptibility patterns need to be taken into account when deciding on treatment.[10] Many antibiotics that were once effective including penicillin, tetracycline and fluoroquinolones are no longer recommended because of high rates of resistance.[10] Cases of resistance to ceftriaxone have been reported but are still rare.[10][10]
As of 2011[update], there are reports of strains of gonorrhea that show antibiotic resistance to multiple agents, specifically to both cefixime and ceftriaxone.[14][15][16][2]
In a 2012 news story, ABC News reported, "A new editorial published in the New England Journal of Medicine highlighted the concern for the rising rate of antibiotic-resistant gonorrhea in the U.S. While the prevalence of resistance to the drug was about .1 percent in 2006, that number jumped to 1.7 percent by mid-2011, the editorial noted."[17]
Partners
It is recommended that sexual partners be tested and potentially treated.[10] One option for treating sexual partners of people infected is patient-delivered partner therapy (PDPT) which involves providing prescriptions or medications to the person to take to their partner without the health care provider first examining them.[18]
Complications
If not treated gonococcal ophthalmia neonatorum will develop in 28% of infants born to women with gonorrhea.
[19]
One of the complication of gonorrhea is systemic dissemination resulting in skin pustules or petechia, septic arthritis, meningitis or endocarditis.[3] This occurs in between 0.6 and 3.0% of women and 0.4 and 0.7% of men.[3]
In men, inflammation of the epididymis (epididymitis); prostate gland (prostatitis) and urethral stricture (urethritis) can result from untreated gonorrhea.[20] In women, the most common result of untreated gonorrhea is pelvic inflammatory disease. Other complications include perihepatitis,[20] a rare complication associated with Fitz-Hugh-Curtis syndrome; septic arthritis in the fingers, wrists, toes, and ankles; septic abortion; chorioamnionitis during pregnancy; neonatal or adult blindness from conjunctivitis; and infertility.
Neonates coming through the birth canal are given erythromycin ointment in the eyes to prevent blindness from infection. The underlying gonorrhea should be treated; if this is done then usually a good prognosis will follow.
Among persons in the United States between 14 and 39 years of age, 46% of people with gonorrheal infection also have chlamydial infection.[21]
Epidemiology
Disability-adjusted life year for gonorrhea per 100,000 inhabitants.
no data
≤10
10–20
20–30
30–40
40–50
50–75
75–100
100–115
115–130
130–145
145–160
≥160
Gonorrhea — Rates: United States, 1941–2007
Gonorrhea is a common infectious disease. WHO estimates that 62 million cases of gonorrhea appear each year.[22]
In the United Kingdom 196 per 100,000 males 20 to 24 years old, and 133 per 100,000 females 16 to 19 years old were diagnosed in 2005.[3] The CDC estimates that more than 700,000 people in the United States get new gonorrheal infections each year. Only about half of these infections are reported to CDC. In 2004, 330,132 cases of gonorrhea were reported to the CDC. After the implementation of a national gonorrhea control program in the mid-1970s, the national gonorrhea rate declined from 1975 to 1997. After a small increase in 1998, the gonorrhea rate has decreased slightly since 1999. In 2004, the rate of reported gonorrheal infections was 113.5 per 100,000 persons.[23]
In the US, it is the second most common bacterial sexually transmitted infections after chlamydia.[24][25] According to the CDC, "Overall, African Americans are most affected by gonorrhea. Blacks accounted for 69% of all gonorrhea cases in 2010."[26]
History
An old patent medicine named "Gono" pitches itself as "Man's Friend for gonorrhea and gleet – an unequalled remedy for unnatural discharges."
It has been suggested that mercury was used as a treatment for gonorrhea. Surgeons' tools on board the recovered English warship the Mary Rose included a syringe that, according to some, was used to inject the mercury via the urinary meatus into any unfortunate crewman suffering from gonorrhea. The name "the clap", in reference to the disease, is recorded as early as the sixteenth century.[1]
Silver nitrate was one of the widely used drugs in the 19th century, but it became replaced by Protargol. Arthur Eichengrün invented this type of colloidal silver, which was marketed by Bayer from 1897 on. The silver-based treatment was used until the first antibiotics came into use in the 1940s.[27][28]
The exact time of onset of gonorrhea as prevalent disease or epidemic cannot be accurately determined from the historical record. One of the first reliable notations occur in the Acts of the (English) Parliament. In 1161 this body passed a law to reduce the spread of "...the perilous infirmity of burning."[29] The symptoms described are consistent with, but not diagnostic of, gonorrhea. A similar decree was passed by Louis IX in France in 1256, replacing regulation with banishment.[30] Similar symptoms were noted at the siege of Acre[disambiguation needed ] by Crusaders.
Coincidental to, or dependent on, the appearance of a gonorrhea epidemic, several changes occurred in European medieval society. Cities hired public health doctors to treat afflicted patients without right of refusal. Pope Boniface[disambiguation needed ] rescinded the requirement that physicians complete studies for the lower orders of the Catholic priesthood.[citation needed]
Medieval public health physicians in the employ of their cities were required to treat prostitutes infected with the "burning", as well as lepers and other epidemic victims.[31] After Pope Boniface completely secularized the practice of medicine, physicians were more willing to treat a sexually transmitted disease.[citation needed]
References
- ^ a b Oxford English Dictionary
- ^ a b Brian Alexander. "Bad bug: Gonorrhea strain resists all antibiotics". msnbc.com. July 11, 2011.
- ^ a b c d e f g h i Moran JS (2007). "Gonorrhoea". Clin Evid (Online) 2007. PMC 2943790. PMID 19454057. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2943790.
- ^ a b Marr, Lisa (2007) [1998]. Sexually Transmitted Diseases: A Physician Tells You What You Need to Know (Second ed.). Baltimore, Maryland: John Hopkins University. ISBN 978-0-8018-8658-4. http://books.google.com/books?id=aywGiP9w-u8C&pg=PT150&dq=gonorrhea+throat&hl=en&sa=X&ei=FcB2T6qYBJOOigK_wLGnDg&ved=0CDsQ6AEwAA#v=onepage&q=gonorrhea%20throat&f=false.
- ^ http://www.gonorrhea-symptoms.com/STD/
- ^ Howard Brown Health Center: STI Annual Report, 2009
- ^ National Institute of Allergy and Infectious Diseases; National Institutes of Health, Department of Health and Human Services (2001-07-20). "Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention". Hyatt Dulles Airport, Herndon, Virginia. pp14
- ^ "webmd – What Can You Catch in Restrooms? -". http://www.webmd.com/balance/features/what-can-you-catch-in-restrooms.
- ^ Barry PM, Klausner JD (March 2009). "The use of cephalosporins for gonorrhea: The impending problem of resistance". Expert Opin Pharmacother 10 (4): 555–77. doi:10.1517/14656560902731993. PMC 2657229. PMID 19284360. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2657229.
- ^ a b c d e f g h Deguchi T, Nakane K, Yasuda M, Maeda S (September 2010). "Emergence and spread of drug resistant Neisseria gonorrhoeae". J. Urol. 184 (3): 851–8; quiz 1235. doi:10.1016/j.juro.2010.04.078. PMID 20643433.
- ^ Meyers D, Wolff T, Gregory K et al (March 2008). "USPSTF recommendations for STI screening". Am Fam Physician 77 (6): 819–24. PMID 18386598.
- ^ http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004526/ section: Prevention
- ^ http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm section: How can gonorrhea be prevented?
- ^ Bolan, GA; Sparling, PF; Wasserheit, JN (2012). "The Emerging Threat of Untreatable Gonococcal Infection". New England Journal of Medicine 366 (6): 485–7. doi:10.1056/NEJMp1112456. PMID 22316442.
- ^ Centers for Disease Control and Prevention (CDC) (July 2011). "Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010". MMWR. Morbidity and mortality weekly report (Centers for Disease Control and Prevention (CDC)) 60 (26): 873–7. PMID 21734634. http://www.cdc.gov/mmwr/pdf/wk/mm6026.pdf.
- ^ Ohnishi, M; Saika, T; Hoshina, S; Iwasaku, K; Nakayama, S; Watanabe, H; Kitawaki, J (January 2011). "Ceftriaxone-Resistant Neisseria gonorrhoeae, Japan". Emerging Infectious Diseases (Centers for Disease Control and Prevention (CDC)) 17 (1): 148–9. doi:10.3201/eid1701.100397. PMC 3204624. PMID 21192886. http://wwwnc.cdc.gov/eid/article/17/1/pdfs/10-0397.pdf.
- ^ "Gonorrhea Resistant to Antibiotics on the Rise". ABC News. February 9, 2012.
- ^ "Expedited partner therapy in the management of sexually transmitted diseases". February 2006. Centers for Disease Control and Prevention (CDC).
- ^ "Prophylaxis for Gonococcal and Chlamydial Ophthalmia Neonatorum in the Canadian Guide to Clinical Preventative Health Care". Public Health Agency of Canada. http://www.phac-aspc.gc.ca/publicat/clinic-clinique/pdf/s1c16e.pdf.
- ^ a b Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; & Mitchell, Richard N. (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. pp. 705–706 ISBN 978-1-4160-2973-1
- ^ Datta, S. D.; Sternberg, M.; Johnson, R. E.; Berman, S.; Papp, J. R.; McQuillan, G.; Weinstock, H. (2007). "Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002". Annals of internal medicine 147 (2): 89–96. PMID 17638719. edit
- ^ "Detection of gonococcal infection : pros and cons of a rapid test.". PubMed.gov.
- ^ "Gonorrhea – CDC Fact Sheet". http://www.cdc.gov/std/Gonorrhea/STDFact-gonorrhea.htm. Retrieved 2008-07-31.
- ^ "CDC – STD Surveillance – Gonorrhea". Archived from the original on 2008-03-06. http://web.archive.org/web/20080306085420/http://www.cdc.gov/std/stats/gonorrhea.htm. Retrieved 2008-08-21.
- ^ "CDC Fact Sheet – Chlamydia". http://www.cdc.gov/std/Chlamydia/STDFact-Chlamydia.htm. Retrieved 2008-08-21.
- ^ "STD Trends in the United States: 2010 National Data for Gonorrhea, Chlamydia, and Syphilis". Centers for Disease Control and Prevention (CDC). 22 November 2010. http://www.cdc.gov/std/stats10/tables/trends-table.htm.
- ^ Max Bender (1898). "Ueber neuere Antigonorrhoica (insbes. Argonin und Protargol)". Archives of Dermatological Research 43 (1): 31–36. doi:10.1007/BF01986890.
- ^ MedlinePlus Encyclopedia Neonatal Conjunctivitis
- ^ W Sanger. History of Prostitution. NY,Harper, 1910 .
- ^ P. LaCroix. The History of Prostitution—Vol. 2. NY,MacMillan, 1931.
- ^ WE Leiky. History of European Morals. NY, MacMillan, 1926.
External links
- "Gonorrhea - CDC Fact Sheet"
Sexually transmitted diseases and infections (STD/STI) (primarily A50–A64, 090–099)
|
|
Bacterial |
- Chancroid (Haemophilus ducreyi)
- Chlamydia/Lymphogranuloma venereum (Chlamydia trachomatis)
- Donovanosis or Granuloma Inguinale (Klebsiella granulomatis)
- Gonorrhea (Neisseria gonorrhoeae)
- Syphilis (Treponema pallidum)
- Ureaplasma infection (Ureaplasma urealyticum)
|
|
Protozoal |
- Trichomoniasis (Trichomonas vaginalis)
|
|
Parasitic |
|
|
Viral |
- AIDS (HIV-1/HIV-2)
- Cervical cancer, vulvar cancer & Genital warts (condyloma), Penile cancer, Anal cancer (Human papillomavirus (HPV))
- Hepatitis B (Hepatitis B virus)
- Herpes simplex (HSV1/HSV2)
- Molluscum contagiosum (MCV)
|
|
General
inflammation |
- female
- Cervicitis
- Pelvic inflammatory disease (PID)
- male
- Epididymitis
- Prostatitis
- either
- Proctitis
- Urethritis/Non-gonococcal urethritis (NGU)
|
|
|
|
noco/cong/npls, sysi/epon
|
proc/asst, drug (G1/G2B/G3CD)
|
|
|
|
noco/cong/tumr, sysi/epon
|
|
|
|
|
Infectious diseases · Bacterial diseases: Proteobacterial G− (primarily A00–A79, 001–041, 080–109)
|
|
α |
Rickettsiales
|
Rickettsiaceae/
(Rickettsioses)
|
Typhus
|
Rickettsia typhi (Murine typhus) · Rickettsia prowazekii (Epidemic typhus, Brill–Zinsser disease, Flying squirrel typhus)
|
|
Spotted
fever
|
Tick-borne
|
Rickettsia rickettsii (Rocky Mountain spotted fever) · Rickettsia conorii (Boutonneuse fever) · Rickettsia japonica (Japanese spotted fever) · Rickettsia sibirica (North Asian tick typhus) · Rickettsia australis (Queensland tick typhus) · Rickettsia honei (Flinders Island spotted fever) · Rickettsia africae (African tick bite fever) · Rickettsia parkeri (American tick bite fever) · Rickettsia aeschlimannii (Rickettsia aeschlimannii infection)
|
|
Mite-borne
|
Rickettsia akari (Rickettsialpox) · Orientia tsutsugamushi (Scrub typhus)
|
|
Flea-borne
|
Rickettsia felis (Flea-borne spotted fever)
|
|
|
|
Anaplasmataceae
|
Ehrlichiosis: Anaplasma phagocytophilum (Human granulocytic anaplasmosis, Anaplasmosis) · Ehrlichia chaffeensis (Human monocytic ehrlichiosis) · Ehrlichia ewingii (Ehrlichiosis ewingii infection)
|
|
|
Rhizobiales
|
Brucellaceae
|
Brucella abortus (Brucellosis)
|
|
Bartonellaceae
|
Bartonellosis: Bartonella henselae (Cat scratch disease) · Bartonella quintana (Trench fever) · either henselae or quintana (Bacillary angiomatosis) · Bartonella bacilliformis (Carrion's disease, Verruga peruana)
|
|
|
|
β |
Neisseriales
|
M+ Neisseria meningitidis/meningococcus (Meningococcal disease, Waterhouse-Friderichsen syndrome, Meningococcal septicaemia)
M- Neisseria gonorrhoeae/gonococcus (Gonorrhea)
ungrouped: Eikenella corrodens/Kingella kingae (HACEK) · Chromobacterium violaceum (Chromobacteriosis infection)
|
|
Burkholderiales
|
Burkholderia pseudomallei (Melioidosis) · Burkholderia mallei (Glanders) · Burkholderia cepacia complex · Bordetella pertussis/Bordetella parapertussis (Pertussis)
|
|
|
γ |
Enterobacteriales
(OX-)
|
Lac+
|
Klebsiella pneumoniae (Rhinoscleroma, Klebsiella pneumonia) · Klebsiella granulomatis (Granuloma inguinale) · Klebsiella oxytoca
Escherichia coli: Enterotoxigenic · Enteroinvasive · Enterohemorrhagic · O157:H7 · O104:H4 (Hemolytic-uremic syndrome)
Enterobacter aerogenes/Enterobacter cloacae
|
|
Slow/weak
|
Serratia marcescens (Serratia infection) · Citrobacter koseri/Citrobacter freundii
|
|
Lac-
|
H2S+
|
Salmonella enterica (Typhoid fever, Paratyphoid fever, Salmonellosis)
|
|
H2S-
|
Shigella dysenteriae/sonnei/flexneri/boydii (Shigellosis, Bacillary dysentery) · Proteus mirabilis/Proteus vulgaris · Yersinia pestis (Plague/Bubonic plague) · Yersinia enterocolitica · Yersinia pseudotuberculosis
|
|
|
|
Pasteurellales
|
Haemophilus: H. influenzae (Haemophilus meningitis, Brazilian purpuric fever) · H. ducreyi (Chancroid) H. parainfluenzae (HACEK)
Pasteurella multocida (Pasteurellosis) · Actinobacillus (Actinobacillosis)
Aggregatibacter actinomycetemcomitans (HACEK)
|
|
Legionellales
|
Legionella pneumophila/Legionella longbeachae (Legionellosis) · Coxiella burnetii (Q fever)
|
|
Thiotrichales
|
Francisella tularensis (Tularemia)
|
|
Vibrionales
|
Vibrio cholerae (Cholera) · Vibrio vulnificus · Vibrio parahaemolyticus · Vibrio alginolyticus · Plesiomonas shigelloides
|
|
Pseudomonadales
|
Pseudomonas aeruginosa (Pseudomonas infection) · Moraxella catarrhalis · Acinetobacter baumannii
|
|
Xanthomonadales
|
Stenotrophomonas maltophilia
|
|
Cardiobacteriales
|
Cardiobacterium hominis (HACEK)
|
|
Aeromonadales
|
Aeromonas hydrophila/Aeromonas veronii (Aeromonas infection)
|
|
|
ε |
Campylobacterales
|
Campylobacter jejuni (Campylobacteriosis, Guillain-Barré syndrome) · Helicobacter pylori (Peptic ulcer, MALT lymphoma) · Helicobacter cinaedi (Helicobacter cellulitis)
|
|
|
|
|
gr+f/gr+a(t)/gr-p(c)/gr-o
|
|
|
|
|